Novo Nordisk A/S buy MoneyMoney
Summary
This prediction ended on 10.08.15 with a price of €49.39. The BUY prediction by MoneyMoney for Novo Nordisk A/S saw massive gains of 31.73%. MoneyMoney has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | -2.926% | -4.228% | 9.878% | 12.466% |
| iShares Nasdaq 100 | 4.462% | 8.605% | 33.063% | 59.465% |
| iShares Nikkei 225® | 0.306% | 0.284% | 3.871% | 4.557% |
| iShares S&P 500 | 2.488% | 4.773% | 27.189% | 50.113% |
Comments by MoneyMoney for this prediction
In the thread Novo Nordisk A/S diskutieren
NOVO NORDISK
Novo Nordisk konnte im vergangenen Jahr den Umsatz , sowie den Reingewinn steigern .
Auch der Ausblick für den neue Jahr ist positiv .
Ausserdem ist noch eine Erhöhung der Dividende geplant .
Stopped prediction by MoneyMoney for Novo Nordisk A/S
Novo Nordisk A/S
03.10.15
04.11.21
05.11.21
